Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 106,723 shares at $18.00 ($1.9M) on 2026-05-04, disclosed to the SEC on 2026-05-06.
Scheduled sale ($1.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.00 | 61 | $1K | 0.1% |
| 2 | $18.00 | 2,466 | $44K | 2.3% |
| 3 | $18.00 | 3,136 | $56K | 2.9% |
| 4 | $18.00 | 6,241 | $112K | 5.8% |
| 5 | $18.03 | 60 | $1K | 0.1% |
| 6 | $18.03 | 2,403 |
| $43K |
| 2.2% |
| 7 | $18.03 | 3,056 | $55K | 2.8% |
| 8 | $18.03 | 6,081 | $110K | 5.7% |
| 9 | $18.18 | 428 | $8K | 0.4% |
| 10 | $18.18 | 17,244 | $313K | 16.2% |
| 11 | $18.18 | 21,926 | $399K | 20.6% |
| 12 | $18.18 | 43,621 | $793K | 41.0% |
| Total | $18.14 avg | 106,723 | $1.9M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-04-30 | $4.2M | — | Filing → |